The burgeoning landscape of therapeutic interventions for weight disorders has witnessed considerable attention focused on GLP-3 analogues and, more recently, the dual GIP and GLP-3 co-agonist retatrutide. While both https://kathryneynm860897.hamachiwiki.com/2069222/glp_3_retatrutide_a_comparative_analysis